We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
- Authors
Sung Han Kim; Sohee Kim; Jungnam Joo; Ho Kyung Seo; Jae Young Joung; Kang Hyun Lee; Jinsoo Chung; Kim, Sung Han; Kim, Sohee; Joo, Jungnam; Seo, Ho Kyung; Joung, Jae Young; Lee, Kang Hyun; Chung, Jinsoo
- Abstract
<bold>Background: </bold>To identify predictors of prolonged or shortened progression-free survival (PFS) and overall survival (OS) among patients with metastatic renal cell carcinoma (mRCC) who received first-line targeted therapies.<bold>Methods: </bold>This retrospective study included 146 patients with mRCC who were treated during 2007-2015. These patients were divided into a group with the worst response (WG), an expected group (EG), and a group with the best response (BG), based on their PFS (≤3 monthsnths, 3-18 monthsnths, and >18 monthsnths, respectively) and OS (<1 year, 1-3 years, and >3 years, respectively). To identify significant predictive factors, the BG and WG were compared to the EG using the Memorial Sloan Kettering Cancer Center and Heng risk models.<bold>Results: </bold>The overall PFS and OS were 9.3 months and 16.4 months, respectively. The median PFS for the WG (41.8 %), EG (45.9 %), and BG (12.3 %) were 2.7 months, 9.3 months, and 56.6 months, respectively, and the median OS for the WG (45.9 %), EG (35.6 %), and BG (18.5 %) were 5.5 months, 21.6 months, and 63.1 months, respectively; these outcomes were significantly different (p < 0.001). Nephrectomy (odds ratio [OR]: 7.15) was a significant predictor of PFS in the BG, and the significant predictors of OS in the BG were MSKCC intermediate risk (OR: 0.12), poor risk (OR: 0.04), and a disease-free interval of <1 year (OR: 0.23) (all, p < 0.05). Anemia (OR: 3.25) was a significant predictor of PFS in the WG, and the significant predictors of OS were age (OR: 1.05), anemia (OR: 4.13), lymphocytopenia (OR: 4.76), disease-free interval of <1 year (OR: 4.8), and synchronous metastasis (OR: 3.52) (all, p < 0.05).<bold>Conclusion: </bold>We identified several significant predictors of unexpectedly good and poor response to first-line targeted therapy among patients with mRCC.
- Subjects
CANCER treatment; NEPHRECTOMY; PROGRESSION-free survival; RENAL cell carcinoma; RETROSPECTIVE studies; PATIENTS; ANTINEOPLASTIC agents; DRUG therapy; HETEROCYCLIC compounds; KIDNEY tumors; METASTASIS; PROGNOSIS; SURVIVAL analysis (Biometry); SULFONAMIDES; UREA; VITAMIN B complex; TREATMENT effectiveness; RAPAMYCIN; INDOLE compounds; VITAMIN therapy; THERAPEUTICS
- Publication
BMC Cancer, 2016, Vol 16, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-016-2615-4